284 related articles for article (PubMed ID: 29454548)
21. 68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes.
Barbaud M; Frindel M; Ferrer L; Le Thiec M; Rusu D; Rauscher A; Maucherat B; Baumgartner P; Fleury V; Colombié M; Thierry-Morel A; Kraeber-Bodéré F; Campion L; Rousseau C
Prostate; 2019 Apr; 79(5):454-461. PubMed ID: 30549066
[TBL] [Abstract][Full Text] [Related]
22.
García Garzón JR; de Arcocha Torres M; Delgado-Bolton R; Ceci F; Alvarez Ruiz S; Orcajo Rincón J; Caresia Aróztegui AP; García Velloso MJ; García Vicente AM;
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):130-138. PubMed ID: 28941866
[TBL] [Abstract][Full Text] [Related]
23. Will
Cuccurullo V; di Stasio GD; Evangelista L; Ciarmiello A; Mansi L
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(2):103-109. PubMed ID: 29422356
[TBL] [Abstract][Full Text] [Related]
24. The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancer.
Meyrick DP; Asokendaran M; Skelly LA; Lenzo NP; Henderson A
Nucl Med Commun; 2017 Nov; 38(11):956-963. PubMed ID: 28922335
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological predictors of positive
Aydin AM; Haberal B; Artykov M; Bilen CY; Yazici S
Ann Nucl Med; 2019 May; 33(5):326-332. PubMed ID: 30778860
[TBL] [Abstract][Full Text] [Related]
26. [PET/CT and biochemical recurrence of prostate adenocarcinoma: Added value of
Gauthé M; Belissant O; Girard A; Zhang Yin J; Ohnona J; Cottereau AS; Nataf V; Balogova S; Pontvert D; Lebret T; Guillonneau B; Cussenot O; Talbot JN
Prog Urol; 2017; 27(8-9):474-481. PubMed ID: 28576423
[TBL] [Abstract][Full Text] [Related]
27. Contribution of
Gómez-de la Fuente FJ; Martínez-Rodríguez I; de Arcocha-Torres M; Quirce R; Jiménez-Bonilla J; Martínez-Amador N; Banzo I
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(3):156-162. PubMed ID: 29137875
[TBL] [Abstract][Full Text] [Related]
28. Detection Rate and Localization of Prostate Cancer Recurrence Using
Kranzbühler B; Müller J; Becker AS; Garcia Schüler HI; Muehlematter U; Fankhauser CD; Kedzia S; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
J Nucl Med; 2020 Feb; 61(2):194-201. PubMed ID: 31375566
[TBL] [Abstract][Full Text] [Related]
29.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
30. Clinical performance of
Kranzbühler B; Nagel H; Becker AS; Müller J; Huellner M; Stolzmann P; Muehlematter U; Guckenberger M; Kaufmann PA; Eberli D; Burger IA
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):20-30. PubMed ID: 29032394
[TBL] [Abstract][Full Text] [Related]
31. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
32. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
33. Assessment of
Gutiérrez-Cardo AL; Pérez Duarte A; García-Argüello SF; López Lorenzo B; Lillo García ME; Valdivielso P
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):22-28. PubMed ID: 30385141
[TBL] [Abstract][Full Text] [Related]
34. Comparison of
Regula N; Kostaras V; Johansson S; Trampal C; Lindström E; Lubberink M; Velikyan I; Sörensen J
Sci Rep; 2020 Mar; 10(1):4993. PubMed ID: 32193430
[TBL] [Abstract][Full Text] [Related]
35. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
36. 68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study.
Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Langkilde NC; Jensen JB; Petersen LJ
Clin Nucl Med; 2018 Aug; 43(8):579-585. PubMed ID: 29916917
[TBL] [Abstract][Full Text] [Related]
37. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
38. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
[TBL] [Abstract][Full Text] [Related]
39. Retrospective correlation of
Onal C; Torun N; Oymak E; Guler OC; Reyhan M; Yapar AF
Ann Nucl Med; 2020 Jun; 34(6):388-396. PubMed ID: 32221791
[TBL] [Abstract][Full Text] [Related]
40. Risk of metastatic disease on
Yaxley JW; Raveenthiran S; Nouhaud FX; Samaratunga H; Yaxley WJ; Coughlin G; Yaxley AJ; Gianduzzo T; Kua B; McEwan L; Wong D
BJU Int; 2019 Sep; 124(3):401-407. PubMed ID: 31141284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
